Yes, Vistaril and Atarax contain the same active molecule — hydroxyzine — but they are not identical products. Atarax is hydroxyzine hydrochloride, while Vistaril is hydroxyzine pamoate, and the two salts differ in milligrams per capsule, absorption behavior, and approved oral forms. Both are first-generation antihistamines used for itching and anxiety, and both carry the same boxed warning about QT prolongation. Swapping one for the other at the same milligram dose is a real prescribing error: 50 mg of Vistaril delivers more hydroxyzine base than 50 mg of Atarax.
The Same Molecule Under Two Different Salts
Hydroxyzine is a first-generation H1 antihistamine, a piperazine derivative with a sedating, anxiolytic profile. The World Health Organization lists it as an essential medicine for itch and anxiety, and the FDA approved it in 1956 (Atarax) with Vistaril following in 1957. The molecule blocks histamine at H1 receptors, but it also binds muscarinic acetylcholine receptors and alpha-1 adrenergic receptors — which explains the dry mouth, blurred vision, and orthostatic dizziness that distinguish it from newer antihistamines like cetirizine.
The salt is the whole story of the naming confusion. Atarax uses hydroxyzine hydrochloride, a small, water-soluble salt. Vistaril uses hydroxyzine pamoate, a large, lipophilic salt that pairs hydroxyzine with pamoic acid. The pamoate portion adds roughly 30% to the molecular weight. That means 100 mg of hydroxyzine pamoate contains about 68 mg of hydroxyzine base. In plain terms: the two bottles can be labeled the same milligram strength and still deliver noticeably different doses of the actual drug.
Mechanism: Why Salt Choice Changes the Drug
When you swallow a hydroxyzine capsule, the salt dissociates in gastric fluid and releases hydroxyzine base, which is then absorbed across the small intestine. The salt's solubility governs how fast that release happens. Hydrochloride dissolves rapidly; pamoate dissolves slowly and more unpredictably. This is not a minor pharmacokinetic footnote — it is why the two products were never intended to be interchangeable milligram-for-milligram.
Hydroxyzine base is highly lipophilic and reaches peak plasma concentration in roughly 2 hours after a hydrochloride dose. The pamoate formulation peaks later, typically 4 to 6 hours, because the salt must first dissolve. Both are metabolized in the liver, primarily via CYP3A4 and CYP2D6, to cetirizine — a metabolite that itself is an active antihistamine. About 20% of hydroxyzine is excreted unchanged in urine. That dual metabolic pathway matters clinically: CYP2D6 poor metabolizers clear hydroxyzine more slowly and may see stronger sedation at the same dose.
The QT story is where mechanism becomes safety. Hydroxyzine delays cardiac repolarization by blocking the hERG potassium channel, and the effect is dose-dependent. The FDA labels for both salts carry a boxed warning about QT prolongation and torsades de pointes, with risk rising above 100 mg per day and compounding with other QT-prolonging drugs. The salt does not change the mechanism — it only changes how fast and how completely the molecule gets into the blood.
Quantified Comparison: Vistaril vs. Atarax
| Feature | Vistaril (hydroxyzine pamoate) | Atarax (hydroxyzine hydrochloride) |
|---|---|---|
| Salt form | Pamoate | Hydrochloride |
| Oral capsule strengths | 25 mg, 50 mg | 10 mg, 25 mg, 50 mg |
| Oral suspension | 25 mg per 5 mL | 10 mg per 5 mL |
| Hydroxyzine base per 50 mg | ~34 mg | ~44 mg |
| Time to peak plasma level | ~4–6 hours | ~2 hours |
| Typical adult itch dose | 25 mg three to four times daily | 10–25 mg three to four times daily |
| Typical adult anxiety dose | 50–100 mg four times daily | 50–100 mg four times daily |
| Maximum labeled daily dose | 400 mg | 400 mg |
| Boxed QT warning | Yes | Yes |
The maximum daily dose is the same number — 400 mg — but it refers to the salt form, not the base. That means the labeled ceiling for hydroxyzine base is roughly 270 mg per day with Vistaril and about 350 mg per day with Atarax. Clinicians who treat "400 mg" as a universal ceiling without checking the salt are working with a hidden 30% variance.
Why the Two Products Exist at All
The dual-salt arrangement is a historical artifact more than a therapeutic design. In the 1950s, Pfizer marketed Atarax for anxiety and Vistaril for a broader mix of indications, including nausea and preoperative sedation. The pamoate salt was favored in some formulations because its slow release reduced peak-related sedation in outpatient use. Neither manufacturer has since streamlined the products, and in 2020 Pfizer discontinued the Vistaril brand while generic hydroxyzine pamoate capsules stayed on the market. Today, most US pharmacies stock hydroxyzine hydrochloride tablets and hydroxyzine pamoate capsules under generic labels, and the brand names survive mostly in older prescribing software and patient memory.
There is also a supply-chain angle. Hydroxyzine hydrochloride is manufactured by more suppliers and is generally cheaper. US cash prices for a 30-day supply run roughly USD 10 to USD 30 for generics, with pamoate capsules occasionally higher during shortage periods. Insurance formularies sometimes prefer one salt over the other for no clinical reason — a substitution a pharmacist may make without flagging the milligram equivalence issue.
Timeline: What Happens After a Single Dose
| Time after dose | Vistaril (pamoate) | Atarax (hydrochloride) |
|---|---|---|
| 0–30 minutes | Minimal absorption | Onset of effect in sensitive patients |
| 1–2 hours | Rising plasma level | Approaching peak |
| ~2 hours | Still absorbing | Peak plasma concentration |
| 3–4 hours | Peak begins | Effect fading in some patients |
| 4–6 hours | Peak plasma concentration | Effect fading in some patients |
| 8–12 hours | Gradual decline | Half-life ~20 hours, gradual decline |
| 24 hours | Mostly cleared | Mostly cleared |
Both salts share an elimination half-life of about 20 hours in adults, which is why twice-daily or three-times-daily dosing still produces cumulative blood levels. Patients over 65 clear hydroxyzine more slowly and are more prone to next-morning sedation. The FDA labels advise starting elderly patients at lower doses and avoiding hydroxyzine entirely in severe renal impairment.
Edge Cases That Change the Answer
Several patient groups make the salt distinction more than academic. In children under 6, hydroxyzine is not FDA-approved, and pediatric dosing is calculated in milligrams of the salt per kilogram — around 0.5 mg/kg per dose for itch — so a switch between salts changes the base dose without any label alarm. In pregnancy, both salts are Category C or comparable, and the choice usually defaults to whichever product the pharmacy stocks.
In liver impairment, hydroxyzine clearance falls, and the difference between a fast-dissolving hydrochloride and a slower pamoate becomes less relevant than the total daily base dose. In patients taking CYP2D6 inhibitors such as fluoxetine or bupropion, hydroxyzine levels rise regardless of salt, and the FDA label recommends avoiding concurrent use. The counterintuitive point: the salt that absorbs fastest (hydrochloride) is not automatically the safer one, because faster peak levels track with the sedation and QT risk that peak around the same time.
A less obvious edge case is the injectable form. Hydroxyzine hydrochloride is available as an intramuscular injection for agitation and preoperative sedation, but pamoate is oral only. A patient transitioning from IM Atarax to oral Vistaril is not just changing salt — they are changing route, absorption, and peak timing all at once.
Common Misconceptions, Corrected
The first misconception is that Vistaril and Atarax are "the same drug, different brand." They share a molecule but not a salt, and the 30% base-content gap makes that phrasing dangerous in a prescription. The second is that higher milligrams mean a stronger effect. A 25 mg Vistaril capsule contains less hydroxyzine base than a 25 mg Atarax tablet, so the "stronger" label belongs to Atarax at equal milligrams — the opposite of what many patients assume from the brand names.
A third misconception is that hydroxyzine is interchangeable with diphenhydramine or cetirizine for everyday allergy relief. It is not a first-line allergy drug; it is used mainly for itch, anxiety, and preoperative sedation. Cetirizine, its own metabolite, is the modern first-line choice for allergic rhinitis because it causes far less sedation at standard doses. Mixing up hydroxyzine with cetirizine is a different error from mixing Vistaril with Atarax, and both happen in real prescriptions.
A fourth, professional caveat: the QT warning is not a reason to avoid hydroxyzine universally, but it is a reason to check electrolytes, review the medication list for other QT-prolonging drugs, and keep the dose at the lowest effective level. The FDA labels for both salts specify that risk increases with dose and with concurrent use of drugs that inhibit CYP3A4.
What to Actually Do
If you are holding a prescription for Vistaril or Atarax, the practical steps are concrete:
- Check the salt, not just the milligram strength, on the bottle or prescription label. Pamoate and hydrochloride are not interchangeable at the same dose.
- Ask a pharmacist to confirm the base equivalent if switching brands or salts, especially for children, elderly patients, or anyone on CYP inhibitors.
- Report palpitations, fainting, or unusual dizziness immediately, since these can signal QT prolongation.
- Avoid alcohol and other sedating antihistamines while taking either product, because sedation stacks.
- Tell every prescriber about both products if you use them for different reasons, so the total daily hydroxyzine dose is tracked in one place.
For most adults with mild itch or short-term anxiety, the clinical difference between the salts is modest at typical doses. The distinction matters most at the edges: high daily doses, pediatric weights, elderly patients, and anyone with cardiac risk factors. In those groups, treating Vistaril and Atarax as identical is the error worth avoiding.